Pulmozyme (dornase alfa), a recombinant human deoxyribonuclease I (rhDNase), has received FDA approval to treat cystic fibrosis (CF) clinically.115Dornase alfa reduces sputum viscosity by hydrolyzing extracellular DNA released from degenerating neutrophils in the sputum of CF patients, thereby facilitating mucus clearance.116Currently, dornase alfa is recommended only for nebulized inhalation. The gene discussed is DNASE1; the disease is cystic fibrosis.